Skip to main content

Table 2 Antiretroviral therapy data of patients in cohort

From: Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India

Characteristics Total patients (n = 1904) Prevalent TB at baseline p-value
No Yes
Total patients, n (%) 1904 (100%) 1267 (66.5%) 637 (33.5%)  
ART regimes (n = 1894)b, n (%) 0.947
 NNRTI based 1482 (78.2%) 983 (66.3%) 499 (33.7%)  
 PI based 413 (21.8%) 275 (66.5%) 138 (33.5%)  
Duration since HIV diagnosis (Months), Median (IQR) a 62 (36.0, 92.0) 61 (34.0, 92.0) 64 (36.0, 94.0) 0.231
Duration on ART (Months), Median (IQR)a 57 (32.0, 84.0) 56 (32.0, 85.0) 60 (32.0, 82.0) 0.382
CD4 count at ART initiation, Median (IQR) a 173 (83.0, 255.0) 197 (112.0, 297.0) 108 (58.0, 182.0) < 0.0001
CD4 count NADIR, Median (IQR) a 146 (72.0, 235.0) 183 (88.0, 277.0) 88 (49.0, 165.0) < 0.0001
Current/updated CD4 count, Median (IQR) a 402 (236, 620) 440 (286, 664) 331 (187, 521) < 0.0001
Virologic condition on ART, n (%) < 0.0001
 Virologic failure (VF) 297 (15.6%) 166 (55.9%) 131 (44.1%)  
 Virologic suppression (VS) 1607 (84.4%) 1101 (68.5%) 506 (31.5%)  
IPT on ART, n (%) 0.001
 ART plus IPT given 358 (18.8%) 264 (73.7%) 94 (26.3%)  
 ART alone 1546 (81.2%) 1003 (64.9%) 543 (35.1%)  
  1. ART antiretroviral therapy, IPT ionized preventive therapy, IQR interquartile range, NNRTI nonnucleoside reverse transcriptase inhibitor, PI protease inhibitor, TB tuberculosis. a Median test, bIntegrase inhibitor based ART regimen was given to 10 patients